Drugs / F-18 THK-5351
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02686216 | Dec 2015 → Apr 2016 | Alzheimer disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03430869 | Mar 2018 → Dec 2021 | major depressive disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 THK-5351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02686216 ↗ |
| Known as | 18F-THK-5351 | “18F-THK-5351 is a novel radiotracer that demonstrates high binding selectivity and affinity for tau pathology” PMID 28336780 ↗ Mar 2017 |
| Modality | Diagnostic / imaging agent | “18F-THK-5351 is a novel radiotracer” PMID 28336780 ↗ Mar 2017 |